Suppr超能文献

儿童和青少年脂蛋白(a):心血管疾病的风险因素还是因果因素?一篇叙述性评论。

Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review.

机构信息

Pediatrics and Neonatology Unit, Centre for Pediatric Dyslipidemias, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.

Department of Translational Medical and Surgical Sciences, University of Parma, 43126 Parma, Italy.

出版信息

Int J Mol Sci. 2024 Aug 13;25(16):8817. doi: 10.3390/ijms25168817.

Abstract

The evaluation of serum Lp(a) values in childhood and adolescence has been widely debated, and in the last few years, many authors have tried to better define Lp(a) role in atherosclerosis pathogenesis, starting from childhood. In our narrative review, we have evaluated the main historical stages of Lp(a) studies in childhood, trying to focus on pathogenic mechanisms linked to elevated serum Lp(a) values, starting from ischemic stroke and vascular damage, and to its possible direct involvement in premature atherosclerosis from childhood onwards. Historic manuscripts on Lp(a) in pediatric patients have mainly focused on serum Lp(a) values and increased stroke risk. More recently, many studies have evaluated Lp(a) as a coronary vascular disease (CVD) risk factor starting from childhood, especially related to a positive family history of premature CVD. Finally, only a few studies evaluated the role of Lp(a) in premature atherosclerotic processes and endothelial and vascular damage in pediatric patients. Lastly, we have hypothesized a future perspective, with the hope that plasma Lp(a) levels will be treated with a tailored pharmacologic approach, and Lp(a) will become a precocious therapeutic target to control the atherosclerotic pathways from the first years of life.

摘要

关于儿童和青少年血清脂蛋白 (a)[Lp(a)] 值的评估一直存在广泛争议,近年来,许多作者试图从儿童期开始,进一步明确 Lp(a) 在动脉粥样硬化发病机制中的作用。在我们的叙述性综述中,我们评估了儿童期 Lp(a) 研究的主要历史阶段,试图专注于与血清 Lp(a) 值升高相关的发病机制,从缺血性卒中和血管损伤开始,并探讨其可能从儿童期开始就直接参与早发性动脉粥样硬化。关于儿科患者血清 Lp(a) 的历史文献主要集中在血清 Lp(a) 值和增加的卒中风险上。最近,许多研究从儿童期开始将 Lp(a) 评估为冠心病 (CVD) 的危险因素,尤其是与早发性 CVD 的阳性家族史相关。最后,只有少数研究评估了 Lp(a) 在儿科患者的早发性动脉粥样硬化过程以及内皮和血管损伤中的作用。最后,我们假设了未来的展望,希望能够通过个体化的药物治疗来控制血浆 Lp(a) 水平,并且 Lp(a) 将成为从生命早期开始控制动脉粥样硬化途径的一个超前治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9c8/11354582/b92a2a3ae049/ijms-25-08817-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验